First-line chemotherapy with liposomal doxorubicin plus cyclofosfamide in metastatic breast cancer: A case report of early and prolonged response

Ferdinando Riccardi, C. Mocerino, C. Barbato, F. Ambrosio, L. Festino, M. G. Vitale, G. Carrillo, M. Trunfio, S. Minelli, G. Cartenì

Research output: Contribution to journalArticlepeer-review

Abstract

The treatment choice for metastatic breast cancer should consider the appropriate balance between efficacy and toxicity of the therapy. We discuss a clinical case with an early response and prolonged to liposomal anthracyclines-based chemotherapy, without cardiotoxicity, enhancing the evidence of safety of liposomal formulation to prevent heart damage. Moreover, the case seems to be of interest for the role of 18F-FDG-PET in clinical response assessment: an early decrease of the standardized uptake value value, even before conventional imaging evaluation, is highly predictive for prolonged clinical response.

Original languageEnglish
Pages (from-to)773-778
Number of pages6
JournalInternational Journal of Immunopathology and Pharmacology
Volume26
Issue number3
Publication statusPublished - Jul 2013

Keywords

  • First-line chemotherapy
  • Metastatic breast cancer
  • Non-pegylated liposomal doxorubicin
  • Positron emission tomography

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'First-line chemotherapy with liposomal doxorubicin plus cyclofosfamide in metastatic breast cancer: A case report of early and prolonged response'. Together they form a unique fingerprint.

Cite this